**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Pilon et al.

Serial No.: 09/898,616

Filed: July 2, 2001

Examiner: Rachel B. Kapust

Group Art Unit: 1647

For: METHODS FOR THE PRODUCTION OF PURIFIED RECOMBINANT
HUMAN UTEROGLOBIN FOR THE TREATMENT OF
INFLAMMATORY AND FIBROTIC CONDITIONSMail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**CERTIFICATE OF MAILING**I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to Mail Stop Amendment, Commissioner for Patents, P.O.
Box 1450, Alexandria, VA 22313-1450 on:

Date: July 19, 2005

Signature:

Henry Cittone**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants respectfully submit this Supplemental Information Disclosure
Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in order to comply with the duty of disclosure
under 37 C.F.R. § 1.56.

I. List of Patents, Publications, or Other Information

References are listed on the attached modified PTO Form No. 1449. It is
respectfully requested that the information be expressly considered during the prosecution of this
application and that the references be made of record therein and appear among the "References
Cited" on any patent to issue therefrom.

07/22/2005 AKELECH1 00000007 09898616

01 FC:1806

180.00 OP

II. Copies

A copy of the listed references is enclosed for the convenience of the Examiner.

Any patents, publications or other information which are listed on the attached modified PTO Form No. 1449 but which are not enclosed herewith were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. 120:

<u>U.S. Serial Number</u>	<u>U.S. Filing Date</u>
08/864,357	05/28/1997

Should the examiner desire, a copy of any of these previously cited unenclosed references can be made available for his convenience.

III. Cross Reference to Related Applications


The Examiner is advised that the following applications belonging to the applicant contain subject matter that may be related to the present application. By bringing these applications to the Examiner's attention, Applicants do not waive the confidentiality provisions of 35 U.S.C. §122.

<u>Serial No.</u>	<u>Filing Date</u>
08/864,357	05/28/1997
09/087,210	05/28/1998
09/120,264	07/21/1998
09/549,926	04/14/2000
09/835,784	04/13/2001
09/861,688	05/21/2001
10/045,534	10/24/2001
10/187,498	07/02/2005
10/638,448	08/11/2003
10/647,371	08/25/2003

A check in the amount of \$180.00 as set forth in 37 C.F.R. § 1.17(p) under 37 C.F.R. § 1.97(c) is enclosed. No additional fee(s) are believed to be due in connection with filing of this Supplemental Information Disclosure Statement. However, the Director is also authorized to charge any such fee(s) deemed necessary or credit any overpayment to Deposit Account No. 50-0540.

Dated: July 19, 2005

Respectfully submitted,



Barry Evans, Reg. No. 22,802
Robert E. Alderson, Reg. No. 44,500
KRAMER LEVIN NAFTALIS & FRANKEL LLP
1177 Avenue of the Americas
New York, New York 10036
(212) 715-9100 (telephone)
(212) 715-8000 (facsimile)

+

+

+

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	8
-------	---	----	---

Application Number	09/898,616
Filing Date	July 2, 2001
First Named Inventor	Pilon et al.
Group Art Unit	1647
Examiner Name	Hunnicatt, Rachel Kapust
Attorney Docket Number	116142/00170

[illegible][illegible]

Date Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	09/898,616
Filing Date	July 2, 2001
First Named Inventor	Pilon et al.
Group Art Unit	1647
Examiner Name	Hunnicatt, Rachel Kapust
Attorney Docket Number	116142/00170

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1.	ABMAN et al., "Pathophysiology and Treatment of Bronchopulmonary Dysplasia: Current Issues." Pediatric Clinics of North America, Vol. 41 No. 2, pp. 277-315 (1994).	
	2.	AKIYAMA et al., "Fibronectin and Integrins in Invasion..." Cancer and Metastasis Reviews. Vol. 14, pp. 173-189 (1995).	
	3.	ANDERSSON et al., "Heterologous Expression of Human Uteroglobulin/Polychlorinated Biphenyl-binding Protein." J. Biol. Chem., Vol. 269 pp.19081-19087 (1994).	
	4.	AOKI et al., "Isolation of Human Uteroglobulin from Blood Filtrate." Mol. Hum. Reprod., Vol. 2, pp. 489-497 (1996).	
	5.	ASSMANN et al., "Familial Glomerulonephritis Characterized by Massive...." Am. J. Kid. Dis., Vol 25, pp. 781-791 (1995).	
	6.	Badcock, N.R. et al., "False-Positive EMIT.RTM.-st.TM. Ethanol Screen with Post-Mortem Infant Plasma", Clinical Chemistry, vol. 38, No. 3: 434-435 (1992).	
	7.	BARNES et al., "Structural Basis for Calcium..." JMB, Vol. 256, pp. 392-404 (1996).	
	8.	BARTON et al., "Amino Acid Sequence Analysis of the ..." Eur. J. Biochem., Vol. 198, pp.749-760 (1991).	
	9.	BEIER, H.M., "Uteroglobulin: A Hormone-dependent Endometrial Protein Involved in blastocyst Development," Biochem. Biophys. Acta, Vol. 160, pp. 289-291 (1968).	
	10.	BERENBAUM, F., "Phospholipase A2 inhibitors: a challenge for the future." Ref. Rhum. Engl. Ed., Vol. 62. pp 409-14 (1995).	
	11.	BERNARD, et al., "Serum Clara Cell Protein: An Indicator..." Env. Res., Vol. 66, pp. 96-104 (1994).	
	12.	BERNARD et al., "Clara Cell Protein in Serum and Bronchoalveolar Lavage," Eur. Respir. J. Vol. 5, pp. 1231-1238 (1992a).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/898,616
		Filing Date	July 2, 2001
		First Named Inventor	Pilon et al.
		Group Art Unit	1647
		Examiner Name	Hunnicatt, Rachel Kapust
Sheet 3 of 8	Attorney Docket Number	116142/00170	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	13.	BERNARD et al., "Human Urinary Protein 1: Evidence for Identity with the Clara Cell Protein and Occurrence in Respiratory Tract and Urogenital Secretions," Clin. Chim. Act., Vol. 207, pp. 239-249 (1992b).	
	14.	BERNARD et al., "Selective Increase in the Urinary Excretion of Protein 1 (Clara Cell protein) and other low molecular weight proteins during normal pregnancy," Scand. J. Clin. Lab. Invest. Vol. 52, pp. 871-878 (1992c).	
	15.	BERNARD et al., "Protein 1 is a Secretory Protein for the Respiratory and Urogenital Tracts Identical to the Clara Cell Protein," Clin. Chem. Vol. 39, pp. 434-435 (1992d).	
	16.	BERNARD et al., "Determination by Latex Immunoassay of Protein 1 in Normal and Pathological Urine," Clin. Chem. Acta, Vol 201, pp. 231-246 (1991).	
	17.	BERNARD et al., "Urine Protein 1: a Sex-Dependent Marker of Tubular or Glomerular Dysfunction," Clin. Chem. Vol. 35, pp. 2141-2142 (1989).	
	18.	BITTERMAN et al., "Role of Fibronectin as a ...," J. Cell. Biol. Vol. 97 pp. 1925-1932 (1983).	
	19.	CAMUSSI et al., "Anti-inflammatory peptides (antiflammins) inhibit synthesis of platelet-activating factor, neutrophil aggregation, and chemotaxis, and intradermal inflammatory reactions," J. Exp. Med., Vol. 171, pp. 913-927 (1995a).	
	20.	CAMUSSI et al., "Antiflammins Inhibit Synthesis of Platelet-Activating....," Biochem. Mol. Biol. and Physiol. of Phospholipase A2 and its Regulatory Factors, pp. 161-172 (1990).	
	21.	CHAN et al., "Antiflammins: Inhibit of Endotoxin-induced Uveitis in Lewis Rats," In Ocular Immunology Today (Usui, Ohno, and Aoki. Eds.) Elsevier Science Publishers, Amsterdam, pp. 467-470 (1990).	
	22.	CHAN et al., "Effects of Antiflammins on Endotoxin-Induced Uveitis in Rats," Arch. Ophthalmol., Vol. 109, pp. 278-281 (1991).	
	23.	CHIESA M et al. "Significant Increase in Immunoregulatory Protein Blastokinin/Uteroglobulin in IgA/Fibronectin Complexes in Sera of Patients with IgA Nephropathy" Nephrology Dialysis Transplantation, Vol. 15, Mo. 9 p. A39 (2000).	
	24.	Daly, H. et al. "Bleomycin Induces Strain-Dependent Alterations in the Pattern of Epithelial Cell-Specific Marker Expression in Mouse Lung", Toxicology and Applied Pharmacology, vol. 142: 303-310 (1993).	
	25.	DENNIS et al., "Multiple forms of phospholipase A2 in macrophages capable of arachidonic acid release for cicosanoid biosynthesis," Adv. Prostaglandin Thromboxane Leukot Res., Vol. 23, pp. 75-80 (1995a).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 8

Complete if Known

Application Number	09/898,616
Filing Date	July 2, 2001
First Named Inventor	Pilon et al.
Group Art Unit	1647
Examiner Name	Hunnicatt, Rachel Kapust
Attorney Docket Number	116142/00170

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	26.	DENNIS E.A., "Potential phospholipase A2s involved in inflammatory diseases," Agents Actions Suppl., Vol. 46, pp 35-39 (1995b).	
	27.	Dhanireddy, R. et al., "Uteroglobin-Like Protein Levels in Premature Infants on Long Term Ventilator Support", Pediatric Research vol. 33, No. 323A, (1993).	
	28.	Dhanireddy, R. et al., "Uteroglobin-Like Protein in Premature Infants: Effect of Gestational Age", Pediatric Research, vol. 23, No. 463A, Abstract No. 1567 (1988).	
	29.	Dhanireddy et al, "Uteroglobin-like Protein in Premature Infants: Effect of Gestational Age," Ped. Res., vol. 23, pp. 463A (1988b).	
	30.	Dhanireddy, R. et al., "Detection of a Rabbit Uteroglobin-Like Protein In Human Neonatal Tracheobronchial Washings", Biochemical and Biophysical Research Communications, vol. 152, No. 3: 1447-1554 (1988).	
	31.	DHANIREDDY et al., "Ontogeny of Uteroglobin in Relation to...", "Pd. Res., 299A.*	
	32.	DIERYNCK et al., "The human Clara cell protein: biochemical and biological...", Mult. Schler., Vol. 1, No. 6, pp. 385-387 (1996).	
	33.	Dierynck, I. et al., "Potent Inhibition of Both Human Interferon-gamma. Production and Biologic Activity By the Clara Cell Protein CC-16", American Journal of Respiratory Cell Molecular Biology, vol. 12: 205-210 (1995).	
	34.	EDELSON et al., "Acute Lung Injury Induced by Phospholipase A ₂ : Structural and Functional Changes," Am Rev. Respir. Dis., Vol. 143, pp 1102-1109 (1991).	
	35.	Facchiano, A. et al., "Inhibition of Pancreatic Phospholipase A.sub.2 Activity By Uteroglobin and Antiflammin Peptides: Possible Mechanism of Action" Life Sciences, vol. 48: 453-646 (1991).	
	36.	Federal Register, published Aug. 16, 1994.	
	37.	Fung, T-C., et al., "Surfactant: Coming of Age for the Treatment of RDA", The Journal of Respiratory Diseases, vol. 13, No. 4: 609-617 (1992).	
	38.	Gerdes, J., et al., "Tracheal Lavage and Plasma Fibronectin: Relationship to Respiratory Distress Syndrome and Development of Bronchopulmonary Dysplasia", The Journal of Pediatrics, pp. 601-606 (1986).	
	39.	Glaser, K.B., "Regulation of Phospholipase A.sub.2 Enzymes: Selected Inhibitors and Their Pharmacological Potential", in Advances In Pharmacology, vol. 32 Academic Press Incorporated, pp. 31-66 (1995).	
	40.	Groneck, P. et al. "Association of Pulmonary Inflammation and Increased Microvascular Permeability During the Development of Bronchopulmonary Dysplasia: A Sequential Analysis of Inflammatory Mediators in Respiratory Fluids of High-Risk Preterm Neonates", Pediatrics, vol. 93 No. 5: 712-718 (1994).	
	41.	GUY et al., "Surfactant-producing Rabbit Pulmonary Alveolar Type II Cells...", BBRC, Vol. 189, pp. 662-669 (1992).	
	42.	Hard, P. et al., "Solution Structure Of A Mammalian PCB-Binding Protein In A Complex With a PCB", Nature Structural Biology, vol. 2, No. 11: 983-989 (1995).	
	43.	Ialenti, A., et al. "Anti-inflammatory Effects of Vasocortin and Nonapeptide Fragments of Uteroglobin and Lipocortin 1 (Antiflammins)", Agents and Actions, vol. 29: 1-2 (1990).	

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/898,616
Filing Date	July 2, 2001
First Named Inventor	Pilon et al.
Group Art Unit	1647
Examiner Name	Hunnicatt, Rachel Kapust
Attorney Docket Number	116142/00170

Sheet	5	of	8
-------	---	----	---

44.	Itoh et al. "Protein 1: Its Purification and Application in Clinical Medicine" J. Clin. Lab. Anal. 7: 394-400 (1993).
45.	Jackson, P. et al., "Purification and Partial Amino Acid Sequence of Human Urine Protein 1", Journal of Chromatograph, 452: 359-367 (1988).
46.	Jorens, P. et al. "Potential Role of Clara Cell Protein, An Endogenous Phospholipase A.sub.2 Inhibitor, In Acute Long Injury" European Respiratory Journal, vol. 8: 1647-1653 (1995).
47.	KIKUKAWA, et al., "Partial Characterization of a Uteroglobin-Like Protein in the Human Uterus and Its Temporal Relationship to Prostaglandin Levels in This Organ," J. Clin. Endo & Met. 67(2): 315-321.
48.	Krishnan, R., "Blastokinin: Inducer and Regulator of Blastocyst Development in the Rabbit Uterus", Science, vol. 158:490-492 (1967).
49.	Kundu, T., et al., "Recombinant Human Uteroglobin Suppresses Cellular Invasiveness Via a Novel Class of High-Affinity Cell Surface Binding Site" Proceedings of the National Academy of Sciences, USA, vol. 93: 2915-2919 (1996).
50.	Lesur, O. Clara Cell Protein (CC-16) In Ensufactant-Associated Protein A (SP-A) an Abbestos-Exposed Workers), chest, vol. 109, No. 2: 467-474 (1996).
51.	Lesur, O. et al. "Clara Cell Protein (CC-16) Induces a Phospholipase A.sub.2 -Mediated in Addition of Fibroblast Migration In vitro" American Journal of Respiratory Critical Care Medicine vol. 152: 290-297 (1995).
52.	Levin, S., et al., "Uteroglobin Inhibits Phospholipase A.sub.2 Activity", Life Sciences, vol. 38: 1813-1819 (1986).
53.	LEYTON et al. "Recombinant Human Uteroglobin Inhibits the In Vitro Invasiveness...", "Cancer Res., Vol. 54 pp 3696-3699 (1994).
54.	Lindhal et al., "Demonstration of different forms of lipocortin-I and Clara cell protein-16 in human nasal and bronchoalveolar lavage fluids", Electrophoresis 20: 881-890 (1999).
55.	Lloret, S. et al., "Effect of Nonapeptide Fragments of Uteroglobin and Lipocortin I on Oedema and Mast Cell Degranulation", European Journal of Pharmacology vol. 264: 379-384 (1994).
56.	Lunardi-Iskandar, Y., et al. "Effects of A Urinary Factor from Women in Early Preganancy of HIV I, SID and associated Disease", Nature Medicine, vol. 4, No. 4: 428-434 (1998).
57.	Manjunath, R. et al. "Inhibition of Thrombin-Induced Platelet Aggregation By Uteroglobin" Biochemical Pharmacology, vol. 36, No. 5-741-746 (1987).
58.	Manjunath, R. et al., "Crosslinking of Uteroglobin By Transglutaminase" Biochemical and Biophysical Research Communications, vol. 121, No. 1: 400-407 (1984).
59.	Mantile, G., et al. "Human Clara Cell 10-kDa Protein is the Counterpart of Rabbit Uteroglobin" Journal of Biological Chemistry, vol. 268, No. 27: 20343-20351 (1993).
60.	MATTHEWS et al., "Crystallization and Characterization of the Recombinant Human Clara Cell 10-kDa Protein", PROTEINS: Structure, Function and Genetics, 20: 191-196 (1994).
61.	Miele, L. et al., "High Level Bacterial Expression of Uteroglobin, A Dimeric Eukaryotic Protein with Two Interchain Disulfide Bridges, in its natural quaternary Structure" Journal of Biological Chemistry, vol. 265, No. 11: 6427-6435 (1990).
62.	Miele, L., et al., "Uteroglobin: Structure, Molecular Biology, and New Perspectives on Its Function as a Phospholipase A.sub.2 Inhibitor" Endocrine Reviews, vol. 8, No. 4: 474-490 (1987).
63.	Miele, L., et al. "Uteroglobin and Uteroglobin-Like Proteins: The Uteroglobin Family of Proteins" Journal of Endocrinology Investigations, vol. 17: 679-692 (1994).
64.	Miele, L. et al. "Novel Anti-Inflammatory Peptides From the Region of Higher Similarity Between Uteroglobin and Lipocortin I", Nature, vol. 335, No. 6192: 726-730 (1988).
65.	Mihal, K., "One gene encoding three proteins with different functions," Am. J. Respir. Cell. Mol. Biol., vol. 5, pp. 1-3 (1991).

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/898,616
Filing Date	July 2, 2001
First Named Inventor	Pilon et al.
Group Art Unit	1647
Examiner Name	Hunnicatt, Rachel Kapust
Attorney Docket Number	116142/00170

Sheet 6 of 8

66.	MUKHERJEE et al., "Modulation of Cellular Response to Antigens by Uteroglobin and Transglutaminase" Adv. Exp. Med. Biol., 231:135-152 (1988).
67.	MUKERJEE et al., "Regulation of Extracellular Phospholipase A2 Activity: Implication for Inflammatory Diseases" DNA and Cell Biology, Vol. 11, No. 3 pp. 233-243 (1992-04).
68.	MUKERJEE A B et al. "Could the Gene Coding for Human Uteroglobin (Clara Cell 10kDa Protein) be a candiate gene for Atopy?" American Journal of Human Genetics Vol. 55 No. 3 pA197 (1994).
69.	Mukherjee, A. et al., "Phospholipase A.sub.2 Enzymes: Regulation and Physiological Role", Biochemical Pharmacology, vol. 48, No. 1: 1-10 (1994).
70.	Nomori, H. "Protein I (Clara Cell) Serum Levels in Healthy Subjects in Patience With Bacterial Pneumonia" American Journal of Respiratory Critial Care Medicine, vol. 152: 746-750 (1995).
71.	Nomori, H., et al. "Protein I and Clara Cell 10-kDa Protein Distribution in Normal and Neoplastic Tissued with Emphasis on the Respiratory System", Virchows Archives, vol. 424: 517-523 (1994).
72.	Nord, M. et al., "Calcium-Dependent Binding of Uteroglobin (PCB-BP/CCSP) Two Negatively Charged Fossil Liposomes" EFEBS Letters vol. 374: 403-406 (1995).
73.	Okutani, R. et al., "Simple and High-Yield Purification of Urine Protein I Using Immunoaffinity Chromatography: Evidence for the Identity of Urine Protein I and Human Clara Cell 10-Kilodalton Protein", Journal of Chromatography, vol. 577: 25-35 (1992).
74.	Olson et al. Know your neighbors: three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell Apr. 1996 5;85(1):1-4.
75.	PERI et al., "Expression of Clara Cell 10-kD Gene in the Human Endometrium and Its Relationship to Ovarian Menstrual Cycle," DNA and Cell Biology, 13(5):495-503 (1994).
76.	PERI A et al., "Uteroglobin Gene Expression in the Rabbit Uterus throughout gestation and in Fetal Lung: Relationship between Uteroglobin and Eicosanoid Levels in the Developing Fetal Lung." Journal of Clinical Investigation, Vol. 96, No. 1 pp 343-353 (1995).
77.	Perri, A. et al., "Tissue-Specific Expression of the Gene Coating For Human Clara Cell 10-kD Protein, a Phospholipase A.sub.2 -Inhibitory Protein", Journal of Clinical Investigations, vol. 92: 2099-2109 (1993).
78.	Peter, W., "Recombinant Rabbit Uteroglobin Expressed at High Levels in E. coli Forms Stable Dimers and Binds Progesterone", Protein Engineering, vol. 3: 61-66 (1989).
79.	Peteres et al, "Clinical determinants of abnormalities in pulmonary functions in survivors of . . .," Am. Rev. Respir. Dis., vol. 139, pp. 1163-1168 (1989).
80.	Piomelli, D., "Arachidonic Acid in Cell Signaling", Current Opinion in Cell Biology, 5: 274-180 (1993).
81.	Ray, M. et al. "Cloning and Characterization of the Mouse Clara Cell Specific 10 kDa Protein Gene Comparison of the 5'-Flanking Region With the Human Rat and Rabbit Gene", Biochemical and Biophysical Research Communications, vol. 197, No. 1: 163-171 (1993).
82.	RENNARD et al., "Production of Fibronectin by the Human Alveolar Macrophase: Mechanism for the Recruitment of Fibroblasts to Sites of Tissue Injury in Interstitial Lung Diseases" Proc. Natl. Acad. Sci. USA, 78(11): 7147-7151 (1988).
83.	Robinson, D., "Macromolecular Transport in Rabbit Blastocysts: Evidence for a Specific Uteroglobin Transport System", Molecular and Cellular Endocrinology, 63: 227-237 (1989).
84.	Ruoslahti et al, "Fibronectin and Its Receptors," Ann. Rev. Biochem., vol. 57, pp. 374-413 (1988).
85.	Shijubo, N. et al. "Serum and BAL Clara Cell 10 kDa Protein (CC10) Levels and CC10-Positive Bronchiolar Cells Are Decreased In Smokers", European Respiratory Journal, vol. 10: 1108-1114 (1997).
86.	Scheuer, W., "Phospholipase A2-regulation and inhibition," Klin Wochenschr, vol. 67, pp. 153-159 (1989).
87.	Singh, G. et al. "Mouse Clara Cell 10-kDa (CC10) Protein: cDNA Nucleotide Sequence and Molecular Basis for the Variation of Progesterone Binding of CC10 from Different Species", Experimental Lung Research vol. 19: 67-75 (1993).



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/898,616
				Filing Date	July 2, 2001
				First Named Inventor	Pilon et al.
				Group Art Unit	1647
				Examiner Name	Hunnicatt, Rachel Kapust
Sheet	7	of	8	Attorney Docket Number	116142/00170

	88.	Singh et al, "Identification, Cellular Localization, Isolation, and Characterization of Human Clara Cell-Specific 10 KD Protein," J. Hist. Cyt., vol. 36, pp. 73-80 (1988b).	
	89.	Singh, G. et al., "Clara Cell 10 kDa protein (CC10): Comparison of Structure and Function to Uteroglobin", Biochimica et Biophysica Acta, 1039:348-355 (1990).	
	90.	Singh, G., et al., "Isolation and Amino Acid Composition of the Isotypes of a Rat Clara Cell Specific Protein", Experimental Lung Research, 13:299-309 (1987).	
	91.	Stenmark et al, "Potential role of cicosanoids and platelet-activating factor in the pathophysiology of BPD," Am. Rev. Resp. Dis., vol. 136, pp. 770-772 (1987).	
	92.	Stripp et al, "Clara cell secretory protein: a determinant of PCB bioaccumulation in mammals," Am. J. Physiol., 271 (Lung Cell Mol. Physiol. 15), pp. L656-L664 (1996).	
	93.	Stripp et al, "Plasticity of airway cell proliferation and gene expression after acute naphthalene injury," Am. J. Physiol., vol. 269, pp. L791-L799 (1995)	
	94.	Stripp, B. et al. "Structure and Regulation of the Murine Clara Cell Secretory Protein Gene", Genomics vol. 20: 27-35 (1994).	
	95.	Stripp, B. et al., "cis-Acting Elements That Confer Lung Epithelial Cell Expression of the CC.sub.10 Gene", Journal of Biological Chemistry, vol. 267, No. 21: 14703-14712 (1992).	
	96.	Tykka et al. A randomized double-blind study using CaNa2EDTA, a phospholipase A2 inhibitor, in the management of human acute pancreatitis. Scan. J. Gastroenterology, (Jan. 1985) 20 (1) 5-12.	
	97.	Tykka et al. Phospholipase A2 inhibitors and their possible clinical use in the treatment of acute pancreatitis. Scand J Gastroenterol 1980;15(5):519-28, Abstract only.	
	98.	Umland et al, "Twist form and function," Nat. Struct. Biol., vol. 2, pp. 919-922 (1995).	
	99.	Umland et al, "Structure of human Clara cell phopholipid-binding protein-ligand complex at 1.9 A resolution," Nature Struct. Biol., vol. 1, pp. 538-545 (1994).	
	100.	VADAS et al, "Potential therapeutic efficacy of inhibitors of...", Agents Actions, Vol. 19, pp. 194-202 (1986).	
	101.	Van Bisbergen et al, "Synthetic peptide from lipocortin 1 has no phospholipase inhibitory activity," FEBS Lett., vol. 247, pp. 293-297 (1989).	
	102.	VAN VYVE et al., "Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects", J. of Allergy and Clin. Immun., vol. 95 no. 1 pp. 60-68 (1995)	
	103.	Van Winkle, L. et al., "Repair of Naphthalene-Injured Microdissected Airways In vitro" American Journal of Respiratory Cell and Molecular Biology, vol. 15: 1-8 (1996).	
	104.	Vasanthakumar, G., "Inhibition of Phagocyte Chemotaxis By Uteroglobin, An Inhibitor of Blastocyst Rejection", Biochemical Pharmacology, vol. 37, No. 3: 389-394 (1988).	
	105.	Volovitz, B. et al., "Relationship Between Leukotriene C4 and a Uteroglobin-Like Protein in Nasal and Tracheobronchial Mucosa of Children" Int. Arch. Allergy Applied Immunology, vol. 86: 420-425 (1988).	
	106.	Vostal, J. et al., "Novel Peptides Derived From a Region of Local Homology Between Uteroglobin and Lipocortin-1 Inhibit Platelet Aggregation and Secretion", Biochemical and Biophysical Research Communications, vol. 165, No. 1: 27-36 (1989).	
	107.	Wu, C., et al. "Integrin Activation and Cytoskeletal Interaction Are Essential for the Assembly of a Fibronectin Matrix", Cell, vol. 83: 715-724 (1995).	
	108.	Wuenschell et al, "Embryonic mouse lung epithelial progenitor cells . . .," J. Histochem Cytochem, vol. 44, pp. 113-123 (1996).	
	109.	Wuenschell, C. et al., "Embryonic Mouse Lung Epithelial Progenitor Cells Co-Express Immunohistochemical Markers of Diverse Mature Cell Lineages", The Journal of Histochemistry and Cytochemistry, vol. 44, No. 2: 113-123 (1996).	
	110.	Zhang, Q. et al., "Cross-linking of the NH.sub.2 -Terminal Region of Fibronectin to Molecules of Large Apparent Molecular Mass", The Journal of Biological Chemistry vol. 271, No. 52: 33284-33292 (1996).	



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/898,616
				Filing Date	July 2, 2001
				First Named Inventor	Pilon et al.
				Group Art Unit	1647
				Examiner Name	Hunnicatt, Rachel Kapust
Sheet	8	of	8	Attorney Docket Number	116142/00170
	111.	Zhang et al, "Modulation of Cell Surface Fibronectin Assembly Sites by Lysophosphatidic Acid," J. Cell Biol., vol. 127, pp. 1447-1459 (1994).			
	112.	WATTS et al., "Effect of Dexamethasone Therapy on Fibronectin and Albumin Levels in Lung Secretions of Infants with Bronchopulmonary Dysplasia" J. Pediat. 121: 597-607 (1992).			
	113.	ZHANG ZH et al., "Severe Fibronectin-Deposit Renal Glomerular Disease in Mice Lacking Uteroglobin." Science, Vol. 276, No. 5317 pp 1408-1412 (1997).			
	114.	ZHANG ZH et al., "Human uteroglobin gene: Structure, subchromosomal localization and polymorphism", DNA and Cell Biology, vol. 16, no. 1 pp. 73-83 (1997).			